Incannex Healthcare Inc. filings document material-event disclosures for a Nasdaq-listed clinical-stage biopharmaceutical company. Recent Form 8-K reports furnish Regulation FD press releases tied to clinical program updates, research partnerships, capital actions and public-company status matters.
The filing record also discloses security and governance matters, including common stock registered on The Nasdaq Stock Market LLC, emerging growth company status, a certificate amendment effecting a 1-for-30 reverse stock split, Nasdaq minimum bid price compliance and capital-structure disclosures. Other material-event filings cover agreement termination, shareholder-rights modifications and related corporate actions.
Incannex Healthcare Inc. filed a Form 8-K to share that it has won the “Best New Technology Solution for Drug Development” honor in the 10th annual MedTech Breakthrough Awards. The award recognizes its lead drug candidate IHL-42X, an oral fixed-dose combination therapy being developed for obstructive sleep apnea.
In the Phase 2 RePOSA trial, IHL-42X produced statistically significant and clinically meaningful reductions in apnea-hypopnea index, with better oxygenation, sleep quality, and fatigue outcomes. Incannex highlights this recognition as supporting its strategy of developing differentiated combination medicines, including IHL-42X for sleep apnea, IHL-675A for inflammatory conditions such as rheumatoid arthritis, and PSX-001 for generalized anxiety disorder.
Incannex Healthcare Inc. furnished a press release describing progress in its PSX-001 oral synthetic psilocybin program for Generalized Anxiety Disorder and its alignment with a new White House Executive Order on psychedelic treatments for serious mental illness.
The company reports PSX-001 showed statistically significant, clinically meaningful benefits across all primary and secondary endpoints in a completed Phase 2 trial involving 73 patients, and notes its U.S. IND is active. Incannex states it is well-funded with over $70 million in cash and no debt, and believes the Executive Order’s directives to prioritize review, enable Right to Try pathways, and initiate DEA rescheduling after successful Phase 3 may reduce regulatory and commercial risk for psilocybin-based therapies.
Incannex Healthcare Inc. has reactivated its previously approved share repurchase program and has already bought back shares over the past two trading days. The board decided to restart buybacks because it believes the company’s market value is too low relative to its cash, clinical progress, and future prospects.
Incannex reports approximately $75 million in cash on hand and no debt following recent financing, giving it flexibility to fund development of IHL-42X for obstructive sleep apnea and PSX-001 for generalized anxiety disorder while repurchasing stock. As of December 31, 2025, about $18.5 million remained available under the repurchase authorization.
The company plans to use the program opportunistically based on market conditions, trading volumes, available capital and broader needs. The buyback authorization does not require any minimum level of repurchases and may be modified, suspended or discontinued at the company’s discretion.
Incannex Healthcare Inc. filed a current report describing a new partnership with the AASM Foundation to support sleep apnea research as its lead drug IHL-42X advances. The company is joining the AASM Foundation’s Corporate Recognition Program and sponsoring a Focused Projects Grant for Junior Investigators on the diagnosis, management, and treatment of sleep apnea, to be awarded in 2026.
The filing highlights recent milestones for IHL-42X, an oral fixed-dose combination of dronabinol and acetazolamide being developed for obstructive sleep apnea, including positive Phase 2 results, FDA Fast Track designation, and progression into the DReAMzz Phase 2 crossover dose-optimisation study ahead of a planned Phase 3 program. Incannex also outlines a broader pipeline that includes IHL-675A for rheumatoid arthritis and PSX-001, a synthetic psilocybin therapy for generalized anxiety disorder.
Incannex Healthcare is highlighting a strong balance sheet following a recently completed financing. The company now holds approximately $75 million in cash with no debt, which management contrasts with a market capitalization of about $46 million, implying a negative enterprise value.
Proceeds from the financing are expected to fund the DReAMzz Phase 2 crossover dose-optimization study for lead candidate IHL-42X in obstructive sleep apnea, while preserving most existing cash for an optimized Phase 3 program. Incannex is also advancing PSX-001 for generalized anxiety disorder under an open FDA IND, and maintains a board-approved share buyback program with remaining capacity. Management views institutional participation in the financing and the company’s cash-rich, debt-free position as external validation of its clinical pipeline and strategy.
Incannex Healthcare Inc. has regained compliance with Nasdaq’s minimum bid price requirement, securing its continued listing on the Nasdaq Capital Market. Nasdaq confirmed the company met the rule after its stock closed at or above $1.00 per share for eleven consecutive business days from February 27 through March 13, 2026.
The company highlights having approximately $75 million in cash and no debt, supporting advancement of its clinical pipeline. Key programs include IHL-42X for obstructive sleep apnea, IHL-675A for inflammatory conditions such as rheumatoid arthritis, and PSX-001 for generalized anxiety disorder.
Incannex Healthcare Inc. is offering 1,997,285 shares of common stock together with accompanying Common Warrants to purchase up to 2,000,000 shares of common stock at a combined unit price of $5.00 per share and accompanying warrant. The offering also includes Pre-Funded Warrants to purchase up to 2,715 shares for eligible investors subject to ownership caps.
The Common Warrants have an exercise price of $6.50 and a five-year term; Pre-Funded Warrants are exercisable for $0.0001 per share. The company estimates net proceeds of approximately $8.9 million, intending to use proceeds for working capital, research and development, and clinical trial expenses. The placement agent is Curvature Securities LLC and delivery is expected on or about March 13, 2026.
Incannex Healthcare Inc. is offering 1,997,285 shares of common stock together with accompanying Common Warrants to purchase up to 2,000,000 shares of common stock at a combined unit price of $5.00 per share and accompanying warrant. The offering also includes Pre-Funded Warrants to purchase up to 2,715 shares for eligible investors subject to ownership caps.
The Common Warrants have an exercise price of $6.50 and a five-year term; Pre-Funded Warrants are exercisable for $0.0001 per share. The company estimates net proceeds of approximately $8.9 million, intending to use proceeds for working capital, research and development, and clinical trial expenses. The placement agent is Curvature Securities LLC and delivery is expected on or about March 13, 2026.
Incannex Healthcare Inc. entered into a securities purchase agreement for a registered direct offering to institutional investors. The company will sell 1,997,285 shares of common stock, pre-funded warrants for up to 2,715 additional shares, and common stock warrants to purchase up to 2,000,000 shares.
The securities are priced at a combined purchase price of $5.0 per share and accompanying warrant, or $4.9999 per pre-funded warrant and accompanying warrant, for expected gross proceeds of about $10 million before fees and expenses. The common warrants have a $6.50 exercise price and a five-year term. Warrant exercises are subject to 4.99% or, at the investor’s option, 9.99% ownership caps, and the company agreed to a 60-day restriction on issuing additional equity after closing.
Incannex Healthcare Inc. entered into a securities purchase agreement for a registered direct offering to institutional investors. The company will sell 1,997,285 shares of common stock, pre-funded warrants for up to 2,715 additional shares, and common stock warrants to purchase up to 2,000,000 shares.
The securities are priced at a combined purchase price of $5.0 per share and accompanying warrant, or $4.9999 per pre-funded warrant and accompanying warrant, for expected gross proceeds of about $10 million before fees and expenses. The common warrants have a $6.50 exercise price and a five-year term. Warrant exercises are subject to 4.99% or, at the investor’s option, 9.99% ownership caps, and the company agreed to a 60-day restriction on issuing additional equity after closing.
Incannex Healthcare Inc. has ended its at-the-market common stock sales arrangement with Curvature Securities and A.G.P./Alliance Global Partners, which allowed it to sell shares from time to time through these agents. Over the life of this Sales Agreement, Incannex raised approximately $108.4 million in aggregate gross proceeds, and the arrangement was terminable at will by the company with no penalty.
The company also updated its corporate investor presentation, now available via its investor relations website and furnished as an exhibit, and issued a press release describing an enhanced Phase 2 dose-optimisation study, which is provided as another exhibit.
Incannex Healthcare Inc. has ended its at-the-market common stock sales arrangement with Curvature Securities and A.G.P./Alliance Global Partners, which allowed it to sell shares from time to time through these agents. Over the life of this Sales Agreement, Incannex raised approximately $108.4 million in aggregate gross proceeds, and the arrangement was terminable at will by the company with no penalty.
The company also updated its corporate investor presentation, now available via its investor relations website and furnished as an exhibit, and issued a press release describing an enhanced Phase 2 dose-optimisation study, which is provided as another exhibit.
Incannex Healthcare Inc. approved and implemented a 1-for-30 reverse stock split of its common stock. Every 30 shares will be combined into 1 share at 4:01 p.m. Eastern Time on February 26, 2026, with trading on a split-adjusted basis beginning February 27, 2026.
The reverse split will reduce outstanding common shares from approximately 358,329,368 as of February 20, 2026 to about 11,944,313, without changing the total number of authorized shares or the par value. Fractional positions will be rounded up to the next whole share, with no cash paid for fractions.
The company states that the reverse split is intended to increase the per-share trading price of its stock to help regain compliance with Nasdaq’s minimum bid price requirement, while existing shareholders retain the same proportional ownership after the adjustment.